RT Book, Section A1 Mills, Edward J. A1 Ioannidis, John P. A. A1 Thorlund, Kristian A1 Schünemann, Holger J. A1 Puhan, Milo A. A1 Guyatt, Gordon A2 Guyatt, Gordon A2 Rennie, Drummond A2 Meade, Maureen O. A2 Cook, Deborah J. SR Print(0) ID 1183877968 T1 Network Meta-analysis T2 Users' Guides to the Medical Literature: A Manual for Evidence-Based Clinical Practice, 3rd ed YR 2015 FD 2015 PB McGraw-Hill Education PP New York, NY SN 978-0-07-179071-0 LK jamaevidence.mhmedical.com/content.aspx?aid=1183877968 RD 2024/10/12 AB CLINICAL SCENARIOYour patient is a 45-year-old woman who experiences frequent migraine headaches that last from 4 to 24 hours and prevent her from attending work or looking after her children. She has exhausted efforts to manage the symptoms with nonsteroidal anti-inflammatory drugs and seeks additional treatment. You decide to recommend a triptan for the patient's migraine headaches but are wondering how to choose from the 7 available triptans. You retrieve a network meta-analysis (NMA) that evaluates the different triptans among this patient population.1 You are not familiar with this type of study, and you wonder if there are special issues to which you should attend in evaluating its methods and results.